A comprehensive long-term retrospective natural history study has provided vital new insights into the progression of EFEMP1-related retinal dystrophy, encompassing both Malattia Leventinese and Doyne Honeycomb Retinal Dystrophy. This research is a critical foundational step for the development of future therapies, as understanding the natural course of the disease is essential for designing effective clinical trials.
The study meticulously tracked the structural and functional changes in the retinas of affected individuals over many years. It confirmed that while the disease is highly penetrant, there is significant phenotypic variability even among family members carrying the same R345W mutation in the EFEMP1 gene. Some patients experience early and severe vision loss, while others maintain relatively good visual acuity well into adulthood despite the presence of extensive drusen.
Key findings highlighted the transition from early drusen accumulation to more advanced stages involving geographic atrophy or choroidal neovascularization. By quantifying these changes using advanced imaging techniques like optical coherence tomography (OCT), researchers have established reliable clinical endpoints.
These endpoints will be invaluable for upcoming clinical trials, such as those evaluating gene therapies or novel cell treatments like SVT-001. Having a clear map of how Malattia Leventinese progresses naturally allows researchers to accurately measure whether a new intervention is successfully halting or reversing the disease.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Genetic testing and clinical management should be performed by qualified healthcare professionals.